Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 2, 2002, Pages 131-136

  Papastavros, Tina ^a   Dolovich, Lisa R ^a   Holbrook, Anne ^a   Whitehead, Lori ^a   Loeb, Mark ^a  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERURICEMIA; LATENT PERIOD; LIVER CELL DAMAGE; MALE; MULTIDRUG RESISTANCE; MUSCULOSKELETAL DISEASE; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; SKIN DISEASE; TUBERCULOSIS;

EID: 0036071110     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country
2. Targeted tuberculin testing and treatment of latent tuberculosis infection
3. Recent advances in epidemiologic research in tuberculosis
4. Chemoprophylaxis of multidrug-resistant tuberculosis infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis
5. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis
6. Asymptomatic hepatitis in persons who received alternative preventative therapy with pyrazinamide and ofloxacin
7. A method for estimating the probability of adverse drug reactions
8. The fluoroquinolones
9. Levofloxacin, a second-generation fluoroquinolone
10. Fluoroquinolone toxicity profiles: A review focusing on newer agents
11. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status
12. Pyrazinamide fulminant hepatitis: An old hepatotoxin strikes again
13. Hepatotoxicity after a short course of low-dose pyrazinamide
14. The role of pyrazinamide in tuberculosis chemotherapy
15. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects